Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [MDPI AG]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不配.应助陈永伟采纳,获得10
刚刚
milian发布了新的文献求助10
2秒前
聪明藏今完成签到,获得积分10
3秒前
我是老大应助zhangpeng采纳,获得10
5秒前
晚菘完成签到,获得积分10
5秒前
珂兰完成签到,获得积分10
7秒前
2899完成签到,获得积分10
8秒前
10秒前
哔哔鱼完成签到,获得积分10
15秒前
16秒前
今后应助坚强枫采纳,获得10
16秒前
18秒前
可乐不加冰完成签到 ,获得积分10
21秒前
舒适斑马发布了新的文献求助10
21秒前
大红参发布了新的文献求助10
22秒前
喜悦发布了新的文献求助10
22秒前
大个应助晚菘采纳,获得10
28秒前
开朗发卡完成签到,获得积分10
29秒前
呵呵喊我完成签到,获得积分10
29秒前
所所应助好远加身采纳,获得10
31秒前
努力科研的博士僧完成签到,获得积分10
34秒前
喜悦完成签到,获得积分20
35秒前
Xxynysmhxs完成签到 ,获得积分10
36秒前
SISU完成签到,获得积分10
37秒前
科研通AI2S应助碳酸芙兰采纳,获得10
38秒前
田様应助锌迹采纳,获得10
39秒前
大个应助zhaoxiao采纳,获得10
42秒前
丰知然应助科研通管家采纳,获得10
42秒前
丰知然应助科研通管家采纳,获得10
42秒前
fifteen应助科研通管家采纳,获得10
42秒前
丰知然应助科研通管家采纳,获得10
42秒前
科研通AI2S应助科研通管家采纳,获得10
43秒前
情怀应助科研通管家采纳,获得10
43秒前
852应助科研通管家采纳,获得10
43秒前
香蕉觅云应助科研通管家采纳,获得10
43秒前
43秒前
浪费完成签到 ,获得积分10
48秒前
52秒前
55秒前
SCI1区完成签到 ,获得积分10
57秒前
高分求助中
Earth System Geophysics 1000
Co-opetition under Endogenous Bargaining Power 666
Medicina di laboratorio. Logica e patologia clinica 600
Handbook of Marine Craft Hydrodynamics and Motion Control, 2nd Edition 500
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Language injustice and social equity in EMI policies in China 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3212399
求助须知:如何正确求助?哪些是违规求助? 2861232
关于积分的说明 8127824
捐赠科研通 2527181
什么是DOI,文献DOI怎么找? 1360785
科研通“疑难数据库(出版商)”最低求助积分说明 643341
邀请新用户注册赠送积分活动 615675